|1.||Chiarani, Fabria: 7 articles (11/2008 - 04/2005)|
|2.||Netto, Carlos Alexandre: 6 articles (10/2008 - 04/2005)|
|3.||Bavaresco, Caren Serra: 6 articles (10/2008 - 04/2005)|
|4.||Yamamoto, Tetsuya: 5 articles (01/2015 - 09/2003)|
|5.||Seifert, Roland: 5 articles (07/2012 - 06/2005)|
|6.||Nyhan, William L: 4 articles (01/2015 - 07/2003)|
|7.||Jinnah, H A: 4 articles (07/2009 - 02/2002)|
|8.||Yamamoto, T: 4 articles (10/2005 - 01/2000)|
|9.||Stover, J F: 4 articles (05/2001 - 05/2000)|
|10.||Unterberg, A W: 4 articles (05/2001 - 05/2000)|
01/01/1977 - "When the hypoxemia was relieved, an increased venous-arterial hypoxanthine difference appeared indicating that the lung metabolism of hypoxanthine was slowed down during alveolar hypoxia. "
01/01/2002 - "The purpose of this study was to asses the usefulness of hypoxanthine (HYP) concentration as an indicator of hypoxia. "
09/01/1990 - "Previous studies using data confounded by age and postmortem sampling time have concluded that postmortem vitreous humor hypoxanthine concentration is a useful indicator of antemortem hypoxia. "
03/09/2009 - "Hypoxanthine release was increased both immediately after hypoxia and 21 h later, however less in hypothermic (median increase 2.0 mumol/L, IQR 1.2-3.2) compared to normothermic cells (2.7 mumol/L, IQR 2.1-4.1, p<0.05). "
04/01/2005 - "Hypoxanthine, a marker of cellular energy failure, increased more with acidotic compared with neutral reoxygenation both after acidotic hypoxia (after 21 h: 7.7+/-2.7 versus 3.1+/-1.9 microM, p<0.001) and after neutral hypoxia (10.4+/-2.6 versus 7.9+/-2.8 microM, p=0.001). "
11/01/1994 - "The metabolic studies showed a significant decrease in hypoxanthine release from a baseline level of 0.4 mumol/L to a paced value of -0.06 mumol/L (P = .002); these very low values would suggest that there is no evidence of ischemia. "
04/01/2013 - "In all organs, a decrease of HEP and an increase in hypoxanthine contents were observed during perfusion and ischemia, irrespective of the donor type. "
01/01/1995 - "Opposite to controls, addition of hypoxanthine to the NBT solution resulted in an increased staining in vessels in the inner nuclear layer in retinas subjected to 30 min of ischemia followed by 3 days of recirculation. "
01/01/1992 - "A rat liver normothermic ischemia-reperfusion model was used to investigate whether hypoxanthine (HXA) that accumulated during ischemia was washed out in hepatic veins during reperfusion. "
01/01/1992 - "Sixty minutes normothermic ischemia in rat liver: the declining tissue concentration of hypoxanthine during reperfusion is not a washout phenomenon."
01/01/2014 - "Our results suggest that aqueous soybean, mistletoe and red clover extracts may exhibit anti-tumoral activity by depleting hypoxanthine concentration in the cancer cells through XO activation, which may lead to lowered salvage pathway activity necessary for the cancer cells to proliferate in the cancerous colon tissue. "
03/01/2011 - "Because the growth of MTAP-deleted tumor cells is dependent on DNPS or hypoxanthine salvage, we would predict such cells to show differential sensitivity to 6-MP and 6-TG. "
02/01/2000 - "However, either PEG-XO or hypoxanthine alone, or native XO with hypoxanthine, showed no effect on the inhibition of tumor growth under present experimental conditions. "
07/01/1984 - "Mean plasma hypoxanthine (Hyp) concentrations determined by high-pressure liquid chromatography were 0.56 microM (range, 0.2 to 1.9 microM) in 16 normal subjects, 0.68 microM (range, 0.1 to 1.1 microM) in 10 untreated acute leukemic subjects, and 0.89 microM (range, 0.3 to 2.6 microM) in 14 solid tumor patients. "
12/01/1988 - "The multiplication of Plasmodium falciparum in culture, as measured by [3H]hypoxanthine incorporation, was inhibited in a dose-dependent manner by rabbit tumor necrosis serum. "
04/01/1991 - "Excess release of hypoxanthine from exercising muscle in two gout patients with partial HGPRTase deficiency: lack of ammonium release."
12/01/1989 - "Oxypurines and uric acid were increased in the plasma of gout patients but only the urinary excretion of hypoxanthine was higher in this group. "
01/01/1989 - "Impaired renal excretion of hypoxanthine and xanthine in primary gout."
10/01/1988 - "The results indicate that the renal excretion of hypoxanthine and xanthine is severely impaired in most patients with primary gout."
10/01/1988 - "Renal excretion of hypoxanthine and xanthine in primary gout."
03/08/2007 - "Inhibition of parasite growth was measured in relation to controls without drugs, either by counting parasitemia in Giemsa-stained blood smears or by measuring the reduction in [(3)H]-hypoxanthine uptake. "
09/01/2004 - "The protocol was then compared to the most commonly used growth measurement methods: parasitemia counting and [(3)H]hypoxanthine incorporation. "
08/01/1995 - "The results indicate that Zn-DFO is superior to DFO, especially at concentrations below 20 microM, as shown by decreased levels of hypoxanthine incorporation, lower levels of parasitemia, and interference with the life cycle of the parasite. "
02/01/1985 - "The study of the growth rate and incorporation of [3H]hypoxanthine and [14C]isoleucine showed that in vitro variations of Plasmodium falciparum parasitemia levels and incorporation rates of the two radiolabeled molecules have been correlated. "
02/01/1983 - "Factors affecting [3H]hypoxanthine incorporation included initial parasitemia, duration of culture, duration of radioisotope pulse, parasite stage, concentration of uninfected erythrocytes, the use of serum or plasma to supplement growth, and the concentration of a variety of purines in the culture medium. "
|5.||Adenosine Triphosphate (ATP)
|9.||Uric Acid (Urate)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|3.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)
|5.||Drug Therapy (Chemotherapy)